Compare Novartis AG (NVS) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Synopsys, Inc. — how do they compare? Novartis AG trades at $139.5 (market cap $262.64B), while Synopsys, Inc. trades at $394 (market cap $75.13B). The key difference: Novartis AG is far larger — about 3.5× Synopsys, Inc.'s market cap, and Novartis AG pays a 3.44% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| NVS | SNPS | |
|---|---|---|
Market Cap | $262.64B | $75.13B |
Sector | Health | Technology |
52-Week High | $168.62 | $534.56 |
52-Week Low | $121.80 | $372.33 |
Enterprise Value | $303.97B | $82.36B |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Synopsys (SNPS) trades at $392.03, down 0.46% on the day, with a bearish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, including Q2 2026 EPS of $3.91 versus $3.67 expected. Revenue growth remains strong, with fiscal 2025 revenue reaching $7.05 billion, though net income margin compressed to 11.43% in 2026. Analyst consensus is overwhelmingly bullish with a $541.88 price target, representing significant upside potential.
The outlook for SNPS is positive based on fundamental strength and Wall Street optimism, but risks include high valuation multiples (P/E of 68.42), competitive pressures in semiconductor software, and integration challenges from the Ansys acquisition. The stock's near-term performance will hinge on Q3 2026 earnings results and continued execution in the expanding AI-driven chip design market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
